Recapitalization - Additional Information (Details) - USD ($) $ in Millions |
12 Months Ended | |
|---|---|---|
Sep. 16, 2022 |
Dec. 31, 2023 |
|
| Business Acquisition [Line Items] | ||
| Severance costs | $ 2.0 | |
| Tyme Therapeutics, Inc. | ||
| Business Acquisition [Line Items] | ||
| Shares issued | 7,500,000 | |
| Number of options and warrants issued | 733,545 | |
| Transaction costs | $ 3.1 | |
| Severance costs | $ 4.5 |
| X | ||||||||||
- Definition NumberOfOptionsAndWarrantsIssuedOnCommonStock No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs. No definition available.
|
| X | ||||||||||
- Definition Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|